Glutamatergic pathways as a target for the treatment of dyskinesias in Parkinson's disease

Biochemical Society Transactions

Volumn 42, Issue 2, 2014, Pages 600-604

  Cenci, M Angela ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Chorea; Drug induced movement disorder; Dyskinesia; Dystonia; Glutamatergic pathway; Neurodegenerative disease; Parkinson's disease

Indexed keywords

3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; AMANTADINE; AMPA RECEPTOR ANTAGONIST; DOPAMINE; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; TOPIRAMATE; TRAXOPRODIL; LEVODOPA;

BASAL GANGLION; BINDING AFFINITY; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG MECHANISM; DYSKINESIA; HUMAN; LEVODOPA INDUCED DYSKINESIA; MOTOR CONTROL; NONHUMAN; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYNAPTIC TRANSMISSION; ANIMAL; DEGENERATIVE DISEASE; DYSTONIA; METABOLISM; PARKINSON DISEASE;

ANIMALS; DYSKINESIAS; DYSTONIA; HUMANS; LEVODOPA; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 84896962028     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST20140006     Document Type: Review

References (50)

1. Cenci, M.A., Ohlin, K.E. and Odin, P. (2011) Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease. CNS Neurol. Disord. Drug Targets 10, 670-684
2. Manson, A., Stirpe, P. and Schrag, A. (2012) Levodopa-induced dyskinesias: clinical features, incidence, risk factors, management and impact on quality of life. J. Parkinson's Dis. 2, 189-198
3. Hagell, P. and Cenci, M.A. (2005) Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective. Brain Res. Bull. 68, 4-15 (Pubitemid 41698871)
4. Lane, E.L., Winkler, C., Brundin, P. and Cenci, M.A. (2006) The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiol. Dis. 22, 334-345
5. Cenci, M.A. (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci. 30, 236-243
6. Cenci, M.A. and Konradi, C. (2010) Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog. Brain Res. 183, 209-233
7. Fieblinger, T., Sebastianutto, I., Alcacer, C., Bimpisidis, Z., Maslava, N., Sandberg, S., Engblom, D. and Cenci, M.A. (2014) Mechanisms of dopamine D1 receptor-mediated ERK1/2 activation in the parkinsonian striatum and their modulation by metabotropic glutamate receptor type 5. J. Neurosci., in the press
8. Fasano, S., Bezard, E., D'Antoni, A., Francardo, V., Indrigo, M., Qin, L., Dovero, S., Cerovic, M., Cenci, M.A. and Brambilla, R. (2010) Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia. Proc. Natl. Acad. Sci. U.S.A. 107, 21824-21829
9. Santini, E., Valjent, E., Usiello, A., Carta, M., Borgkvist, A., Girault, J.A., Herve, D., Greengard, P. and Fisone, G. (2007) Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J. Neurosci. 27, 6995-7005 (Pubitemid 47015907)
10. Westin, J.E., Vercammen, L., Strome, E.M., Konradi, C. and Cenci, M.A. (2007) Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol. Psychiatry 62, 800-810 (Pubitemid 47374647)
11. Sgambato-Faure, V. and Cenci, M.A. (2012) Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog. Neurobiol. 96, 69-86
12. Chase, T.N., Oh, J.D. and Konitsiotis, S. (2000) Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J. Neurol. 247 (Suppl. 2), II36-II42
13. Fox, S.H., Katzenschlager, R., Lim, S.Y., Ravina, B., Seppi, K., Coelho, M., Poewe, W., Rascol, O., Goetz, C.G. and Sampaio, C. (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the motor symptoms of Parkinson's disease. Mov. Disord. 26 (Suppl. 3), S2-S41
14. Ahmed, I., Bose, S.K., Pavese, N., Ramlackhansingh, A., Turkheimer, F., Hotton, G., Hammers, A. and Brooks, D.J. (2011) Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain 134, 979-986
15. Dupre, K.B., Ostock, C.Y., Eskow Jaunarajs, K.L., Button, T., Savage, L.M., Wolf, W. and Bishop, C. (2011) Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp. Neurol. 229, 288-299
16. Mela, F., Marti, M., Bido, S., Cenci, M.A. and Morari, M. (2012) In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. Neurobiol. Dis. 45, 573-582
17. Picconi, B., Centonze, D., Hakansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M.A. and Calabresi, P. (2003) Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci. 6, 501-506 (Pubitemid 36514698)
18. Picconi, B., Paille, V., Ghiglieri, V., Bagetta, V., Barone, I., Lindgren, H.S., Bernardi, G., Cenci, M.A. and Calabresi, P. (2008) L-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation. Neurobiol. Dis. 29, 327-335
19. Paoletti, P., Bellone, C. and Zhou, Q. (2013) NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci. 14, 383-400
20. Calon, F., Morissette, M., Ghribi, O., Goulet, M., Grondin, R., Blanchet, P.J., Bedard, P.J. and Di Paolo, T. (2002) Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 26, 127-138 (Pubitemid 34045159)
21. Calon, F., Rajput, A.H., Hornykiewicz, O., Bedard, P.J. and Di Paolo, T. (2003) Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis. 14, 404-416 (Pubitemid 37543519)
22. Chase, T.N. and Oh, J.D. (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 23, S86-S91
23. Nutt, J.G., Gunzler, S.A., Kirchhoff, T., Hogarth, P., Weaver, J.L., Krams, M., Jamerson, B., Menniti, F.S. and Landen, J.W. (2008) Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov. Disord. 23, 1860-1866
24. Gardoni, F., Picconi, B., Ghiglieri, V., Polli, F., Bagetta, V., Bernardi, G., Cattabeni, F., Di Luca, M. and Calabresi, P. (2006) A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. J. Neurosci. 26, 2914-2922
25. Seeburg, P.H. (1993) The TINS/TiPS Lecture: the molecular biology of mammalian glutamate receptor channels. Trends Neurosci. 16, 359-365
26. Bibbiani, F., Oh, J.D., Kielaite, A., Collins, M.A., Smith, C. and Chase, T.N. (2005) Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp. Neurol. 196, 422-429 (Pubitemid 41607831)
27. Kobylecki, C., Cenci, M.A., Crossman, A.R. and Ravenscroft, P. (2010) Calcium-permeable AMPA receptors are involved in the induction and expression of L-DOPA-induced dyskinesia in Parkinson's disease. J. Neurochem. 114, 499-511
28. Konitsiotis, S., Blanchet, P.J., Verhagen, L., Lamers, E. and Chase, T.N. (2000) AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54, 1589-1595 (Pubitemid 30226801)
29. Silverdale, M.A., Nicholson, S.L., Crossman, A.R. and Brotchie, J.M. (2005) Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Mov. Disord. 20, 403-409 (Pubitemid 40779014)
30. Kobylecki, C., Hill, M.P., Crossman, A.R. and Ravenscroft, P. (2011) Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease. Mov. Disord. 26, 2354-2363
31. Pin, J.P. and Duvoisin, R. (1995) The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34, 1-26
32. Conn, P.J., Battaglia, G., Marino, M.J. and Nicoletti, F. (2005) Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat. Rev. Neurosci. 6, 787-798 (Pubitemid 41679241)
33. Dekundy, A., Pietraszek, M., Schaefer, D., Cenci, M.A. and Danysz, W. (2006) Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res. Bull. 69, 318-326
34. Mela, F., Marti, M., Dekundy, A., Danysz, W., Morari, M. and Cenci, M.A. (2007) Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J. Neurochem. 101, 483-497 (Pubitemid 46525288)
35. Rylander, D., Recchia, A., Mela, F., Dekundy, A., Danysz, W. and Cenci, M.A. (2009) Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J. Pharmacol. Exp. Ther. 330, 227-235
36. Halassa, M.M. and Haydon, P.G. (2010) Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. Annu. Rev. Physiol. 72, 335-355
37. Koehler, R.C., Roman, R.J. and Harder, D.R. (2009) Astrocytes and the regulation of cerebral blood flow. Trends Neurosci. 32, 160-169
38. Hirano, S., Asanuma, K., Ma, Y., Tang, C., Feigin, A., Dhawan, V., Carbon, M. and Eidelberg, D. (2008) Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. J. Neurosci. 28, 4201-4209
39. Ohlin, K.E., Sebastianutto, I., Adkins, C.E., Lundblad, C., Lockman, P.R. and Cenci, M.A. (2012) Impact of L-DOPA treatment on regional cerebral blood flow and metabolism in the basal ganglia in a rat model of Parkinson's disease. NeuroImage 61, 228-239
40. Berg, D., Godau, J., Trenkwalder, C., Eggert, K., Csoti, I., Storch, A., Huber, H., Morelli-Canelo, M., Stamelou, M., Ries, V. et al. (2011) AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov. Disord. 26, 1243-1250
41. Gregoire, L., Morin, N., Ouattara, B., Gasparini, F., Bilbe, G., Johns, D., Vranesic, I., Sahasranaman, S., Gomez-Mancilla, B. and Di Paolo, T. (2011) The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys. Parkinsonism Relat. Disord. 17, 270-276
42. Johnston, T.H., Fox, S.H., McIldowie, M.J., Piggott, M.J. and Brotchie, J.M. (2010) Reduction of l-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J. Pharmacol. Exp. Ther. 333, 865-873
43. Morin, N., Gregoire, L., Gomez-Mancilla, B., Gasparini, F. and Di Paolo, T. (2010) Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 58, 981-986
44. Rylander, D., Iderberg, H., Li, Q., Dekundy, A., Zhang, J., Li, H., Baishen, R., Danysz, W., Bezard, E. and Cenci, M.A. (2010) A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol. Dis. 39, 352-361
45. Stocchi, F., Rascol, O., Destee, A., Hattori, N., Hauser, R.A., Lang, A.E., Poewe, W., Stacy, M., Tolosa, E., Gao, H. et al. (2013) AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov. Disord. 28, 1838-1846
46. Iderberg, H., Rylander, D., Bimpisidis, Z. and Cenci, M.A. (2013) Modulating mGluR5 and 5-HT1A/1B receptors to treat L-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action. Exp. Neurol. 250, 116-124
47. Bennouar, K.E., Uberti, M.A., Melon, C., Bacolod, M.D., Jimenez, H.N., Cajina, M., Kerkerian-Le Goff, L., Doller, D. and Gubellini, P. (2013) Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: implications for Parkinson's disease treatment and dyskinesia. Neuropharmacology 66, 158-169
48. Jones, C.K., Bubser, M., Thompson, A.D., Dickerson, J.W., Turle-Lorenzo, N., Amalric, M., Blobaum, A.L., Bridges, T.M., Morrison, R.D., Jadhav, S. et al. (2012) The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. J. Pharmacol. Exp. Ther. 340, 404-421
49. Le Poul, E., Bolea, C., Girard, F., Poli, S., Charvin, D., Campo, B., Bortoli, J., Bessif, A., Luo, B., Koser, A.J. et al. (2012) A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease. J. Pharmacol. Exp. Ther. 343, 167-177
50. Lopez, S., Bonito-Oliva, A., Pallottino, S., Acher, F. and Fisone, G. (2011) Activation of metabotropic glutamate 4 receptors decreases L-DOPA-induced dyskinesia in a mouse model of Parkinson's disease. J. Parkinson's Dis. 1, 339-346